Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Aug 9;3(15):e120858.
doi: 10.1172/jci.insight.120858.

Personalized therapy for lung cancer: striking a moving target

Suchita Pakkala, Suresh S Ramalingam
Review

Personalized therapy for lung cancer: striking a moving target

Suchita Pakkala et al. JCI Insight. .

Abstract

Molecular targeted therapy heralded a new era for the treatment of patients with oncogene-driven advanced-stage non-small-cell lung cancer (NSCLC). Molecular testing at the time of diagnosis guides therapy selection, and targeted therapies in patients with activating mutations in EGFR, BRAF, and rearrangements in anaplastic lymphoma kinase (ALK) and ROS1 have become part of routine care. These therapies have extended the median survival from a mere few months to greater than 3 years for patients with stage 4 disease. However, despite the initial success, these treatments are eventually met with molecular resistance. Selective pressure leads to cellular adaption to maintain cancer growth, making resistance complex and the treatment challenging. This review focuses on recent advances in targeted therapy, mechanisms of resistance, and therapeutic strategies to overcome resistance in patients with lung cancer.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: SSR has served on scientific advisory board meetings and received honoraria from Amgen, Abbvie, AstraZeneca, Bristol Myers Squibb, Genentech, Roche, Merck, Nektar, and Loxo Oncology.

Figures

Figure 1
Figure 1. Treatment algorithm for stage 4 non–small-cell lung cancer.
Molecular testing is used to identify patients that are candidates for targeted therapies based on mutations. Applicable therapies for EGFR mutation include osimertinib, erlotinib, gefitinib, and afatinib; for anaplastic lymphoma kinase gene (ALK) mutation include alectinib, crizotinib, and ceritinib; second-line brigatinib; for c-ros oncogene 1 (ROS1) mutation include crizotinib and ceritinib; for v-raf murine sarcoma viral oncogene homolog B1 (BRAF) V600E include dabrafenib plus trametinib. Targeted therapy with activity against other genetic alterations have been identified for rearranged during transfection (RET) mutation (cabozantinib, vandetanib), for mesenchymal-to-epithelial transition (MET), amplification or exon 14 mutation (crizotinib) or human epidermal growth factor receptor 2 (HER2) mutation (ado-trastuzumab emtansine). Patients without actionable mutations will be tested for PDL1 expression, and treatment is determined by the overall level of expression and tumor mutational burden (TMB).
Figure 2
Figure 2. Genomic classification of lung adenocarcinoma.
The incidence of specific genetic mutations in NSCLC is reported, with mutations in KRAS, EGFR, and ALK having the highest prevalence.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. National Lung Screening Trial Research Team, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395–409. doi: 10.1056/NEJMoa1102873. - DOI - PMC - PubMed
    1. Schiller JH, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346(2):92–98. doi: 10.1056/NEJMoa011954. - DOI - PubMed
    1. Scagliotti GV, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol. 2002;20(21):4285–4291. doi: 10.1200/JCO.2002.02.068. - DOI - PubMed
    1. Sweeney CJ, et al. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic nonsmall cell lung carcinoma. Cancer. 2001;92(10):2639–2647. doi: 10.1002/1097-0142(20011115)92:10<2639::AID-CNCR1617>3.0.CO;2-8. - DOI - PubMed
    1. Fukuoka M, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected] J Clin Oncol. 2003;21(12):2237–2246. doi: 10.1200/JCO.2003.10.038. - DOI - PubMed

MeSH terms